Funding Opportunity PAR-25-154 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Funding Opportunity PAR-25-277 from the NIH Guide for Grants and Contracts. The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this NOFO is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community.This NOFO seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK.

Funding Opportunity PAR-25-346 from the NIH Guide for Grants and Contracts. Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Notice NOT-CA-25-020 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-045 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-029 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This NOFO will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Funding Opportunity RFA-AI-24-080 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support the development of improved products for treating Botulinum Neurotoxin (BoNT) intoxication. Development of products that can reverse BoNT intoxication are highly encouraged. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R61 phase.

Funding Opportunity PAR-25-296 from the NIH Guide for Grants and Contracts. The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.

Funding Opportunity RFA-NR-25-003 from the NIH Guide for Grants and Contracts. The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support unusually innovative intervention research addressing social determinants of health (SDOH) which, if successful, would have a major impact on preventing, reducing, or eliminating health disparities and advancing health equity. Projects should clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on advancing NIHs commitment to addressing SDOH to accelerate progress in improving health for all. Preliminary data are not required for this initiative.

Funding Opportunity PAR-25-321 from the NIH Guide for Grants and Contracts. Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Notice NOT-OD-25-036 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-013 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-019 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-157 from the NIH Guide for Grants and Contracts. The National Center for Advancing Translational Sciences (NCATS) invites applications for the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) Notice of Funding Opportunity (NOFO) to foster investigator-initiated development of highly innovative technologies to address barriers, limitations, or bottlenecks in translational science particularly for therapeutic development. This program will support the early-stage proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development, which can transform or significantly improve the efficiency of therapeutic development to achieve NCATS ultimate goals - more treatments to all people more quickly. The research proposed should be for the development of technology that can break new ground or extend present technology toward new directions or novel applications. With this initiative, we expect to support the development and/or prototyping of new technologies that will lead to improved efficiency in the therapeutic development pipeline.

Notice NOT-OD-25-030 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-045 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or that develop needed statistical methodology for analyzing existing dental, oral or craniofacial databases.

Notice NOT-OD-25-029 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-074 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-044 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-224 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing a comprehensive understanding of the impact of sex differences on the trajectories of brain aging and disease, phenotypes of AD and AD-related dementias (ADRD) risk, individualized prevention, and responsiveness to pharmacologic and non-pharmacologic interventions. To this end, the central goal of this initiative is to develop robust research programs that will explore how genes, environment, and host factors such as hormonal status (gonadal and brain-derived) interact at various levels of biologic complexity (i.e., cell, tissue, organs/organ systems, and populations) to produce heterogeneous phenotypes of disease risk and responsiveness to prevention/therapy in AD/ADRD.